RxDoctor Payments Data

Emily Kachelmeyer

Gerontology · Summerville, SCNPI 1396466991

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,171, more than ten times the $120 reported in 2022. Among gerontology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,477in general payments, 2019–2025

Across 324 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$885
  • Xeris Pharmaceuticals, Inc.$735
  • Amgen$692
  • Insulet Corporation$614
  • Sanofi-aventis U.S. LLC$531
  • Novo Nordisk$469
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,477100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,477 in reported general payments places this provider in the 90th percentile of 137 gerontology providers in South Carolina.

See all gerontology providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide136$176,494
TrulicityDulaglutide67$80,936
JardianceEmpagliflozin46$66,771
FarxigaDapagliflozin Propanediol43$62,801
OzempicSemaglutide35$55,526
Tresiba Flextouch U-200Insulin Degludec21$42,420
Tresiba Flextouch U-100Insulin Degludec20$24,062
JanuviaSitagliptin Phosphate11$17,546
SynjardyEmpagliflozin/Metformin Hcl11$11,935
Liothyronine Sodium123$6,618
Novolog FlexpenInsulin Aspart17$5,394
SynthroidLevothyroxine Sodium55$5,215
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,731
TirosintLevothyroxine Sodium15$4,624
Humalog Kwikpen U-100Insulin Lispro14$3,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$885$257,430203 claims
Boehringer IngelheimJardiance, Synjardy$93$78,70657 claims
AstraZenecaFarxiga$170$62,80143 claims
Novo NordiskOzempic$469$55,52635 claims
AbbVieSynthroid$67$5,21555 claims
IBSA Pharma Inc.Tirosint$111$4,62415 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$2,648194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 137 gerontology providers in South Carolina.

Other gerontology in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →